Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer

Urology

Volumn 62, Issue SUPPL. 1, 2003, Pages 79-86

  Hellerstedt, Beth ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANDROGEN; ANILIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ENZYME INHIBITOR; GONADORELIN; TUMOR PROTEIN;

CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; GYNECOMASTIA; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; LIVER DISEASE; MASTALGIA; MONOTHERAPY; MORBIDITY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BLOOD; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG POTENTIATION; MALE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROSTATE TUMOR; PROSTATECTOMY; SALVAGE THERAPY; TUMOR RECURRENCE;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIETHYLSTILBESTROL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FINASTERIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 1842840803     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.09.002     Document Type: Article

References (39)

1. The Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011-1017, 1967.
2. Blackard CE, Byar DP, and Jordan WP: Orchiectomy for advanced prostatic carcinoma: a re-evaluation. Urology 1: 553-560, 1973.
3. Chadwick DJ: Medical or surgical castration: the patient's choice. Curr Opin Urol 2: 256-258, 1992.
4. Potosky AL, Knopf K, Clegg L, et al: Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 17: 3750-3757, 2001.
5. Denis L: European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. Urology 51: 50-57, 1998.
6. Tunn UW, Bargelloni U, Cosciani S, et al: Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int 60: 9-16, 1998.
7. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
8. Denis L, Robinson M, Mahler C, et al: Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853). J Steroid Biochem Mol Biol 37: 951-959, 1990.
9. Boccardo F, Pace M, Robagotti A, et al: Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 29: 1088-1093, 1993.
10. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036-1042, 1998.
11. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355: 1491-1498, 2000.
12. Tyrrell CJ, Kaisary AV, Iversen P, et al: A randomised comparison of bicalutamide 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33: 447-456, 1998.
13. Iversen P, Tyrrell CJ, Kaisary AV, et al: Bicalutamide 150 mg monotherapy compared with castration in patients with non-metastatic, locally-advanced prostate cancer: 6.3 years follow-up. J Urol 164: 1579-1582, 2000.
14. Fleshner NE, and Trachtenberg J: Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 154: 1642-1645, 1995.
15. Ornstein DK, Rao GS, Johnson B, et al: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 48: 901-905, 1996.
16. Brufsky A, Fontaine-Rothe P, Berlane K, et al: Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49: 913-920, 1997.
17. Kirby R, Robertson C, Turkes A, et al: Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. Prostate 40: 105-114, 1999.
18. Ornstein DK, Smith DS, and Andriole GL: Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 52: 1094-1097, 1998.
19. Bailar JD, and Byar DP: Estrogen treatment for cancer of the prostate: early results with 3 doses of diethylstilbestrol and placebo. Cancer 26: 257-261, 1970.
20. Byar DP, and Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7: 165-170, 1988.
21. De Voogt HJ, Smith PH, Pavone-Macaluso M, et al: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 135: 303-307, 1986.
22. Robertson CN, Roberson KM, Padilla GM, et al: Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 88: 908-917, 1996.
23. 2+ in PC3 human prostate cancer cells. Prostate 47: 141-148, 2001.
24. Castagnetta L, and Carruba G: Human prostate cancer: a direct role for oestrogens. Ciba Found Symp 191: 286-289, 1995.
25. Carruba G, Miceli D, D'Amico D, et al: Sex-steroids upregulate E-cadherin expression in hormone responsive LN-CaP human prostate cancer cells. Biochem Biophys Res Commun 212: 624-631, 1995.
26. Scherr D, Pitts WR, and Vaughan ED: Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 167: 535-538, 2002.
27. McLeod D, Zinner N, Tomera K, et al: A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58: 756-761, 2001.
28. Trachtenberg J, Gittleman M, Steidle C, et al: A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 167: 1670-1674, 2002.
29. Bruchovsky N, Rennie PS, Coldman AJ, et al: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282, 1990.
30. Klotz LH, Herr HW, Morse MJ, et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58: 2546-2550, 1986.
31. Oefelein MG: Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology 54: 694-699, 1999.
32. Bouchot O, Lenormand L, Karam G, et al: Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 38: 543-549, 2000.
33. De La Taille A, Zerbib M, Conquy S, et al: Intermittent androgen suppression in patients with prostate cancer. BJU Int 91: 18-22, 2003.
34. Goldenberg SL, Gleave ME, Taylor D, et al: Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years follow-up. Mol Urol 3: 287-292, 1999.
35. Grossfeld GD, Small EJ, Lubeck DP, et al: Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology 58(suppl 2A): 56-64, 2001.
36. Higano CS, Ellis W, Russell K, et al: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48: 800-804, 1998.
37. Crook JM, Szumacher E, Malone S, et al: Intermittent androgen suppression in the management of prostate cancer. Urology 53: 530-534, 1999.
38. Calais F, Bono A, Whelan P, et al: Phase III study of intermittent MAB versus continuous MAB international cooperative study [abstract]. Eur Urol 41(suppl 1): 531a, 2002.
39. Waltregny D, Boca P, Nicolas H, et al: Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a randomized prospective multicenter clinical trial [abstract]. J Urol 167(suppl): 701a, 2002.